Chemical analysis tools maker 908 Devices Q2 revenue beats estimates, raises FY forecast

908 Devices

05/08/2025 12:37

Overview

908 Devices Q2 revenue grows 14% yr/yr, beating analyst expectations

Company raises 2025 revenue outlook, indicating confidence in future growth

Net loss of $13.3 mln in Q2, following restructuring and strategic acquisitions

Outlook

908 Devices raises 2025 revenue outlook to $54 mln-$56 mln, for 13%-17% growth

Result Drivers

HANDHELD PRODUCT GROWTH - Revenue increase driven by growth in handheld product and service revenue

DEVICE LAUNCHES - Record placements of XplorIR and launch of VipIR contributed to revenue growth

RESTRUCTURING IMPACT - Manufacturing consolidation and restructuring efforts strengthened financial profile

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$13 mln
$12.20 mln (4 Analysts)
Q2 EPS
-$0.37
Q2 Net Income
Miss
-$13.30 mln
-$5.79 mln (3 Analysts)
Q2 Gross Profit
$6.40 mln
Q2 Operating Expenses
$21.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for 908 Devices Inc is $6.50, about 0.3% below its August 4 closing price of $6.52

Press Release: ID:nBw5BbJ63a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)